Dr Churchman speaks with ecancertv at ASH 2016 about the mutations in IKZF1, or Ikaros, that are associated with worse outcomes for childhood leukaemia.
She outlines a suite of heritable mutations which result in a stem-like behaviour, cell adhesion and drug resistance within the bone marrow.
Dr Churchman explains how next generation sequencing could help in identifying patients most suited to targeted therapy.
ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.